The Mongolian government has approved a regulation requiring the purchase of pharmaceuticals, medical supplies, and vaccines from a single source. This initiative focuses on securing 16 essential medicines and treatments for hemophilia from internationally recognized manufacturers, resulting in savings of 3.15 billion Mongolian Tugrik and a 10%+ profit margin. This centralized procurement model, common in countries like South Korea, Japan, and New Zealand, allows for bulk discounts and access to WHO-regulated, high-quality products. Benefits include reduced national budget expenditure, a stable supply of scarce medications, and importantly, protection against substandard and counterfeit drugs. Health Minister E. Batshugar emphasized this system will alleviate the financial burden on citizens by controlling drug price increases and ensuring access to affordable, quality healthcare. The new regulation prioritizes patient safety and fiscal responsibility within the pharmaceutical sector.